
  
    
      
        Introduction_NNP
        Although_IN juvenile_JJ rheumatoid_NN arthritis_NN (_( JRA_NNP )_) is_VBZ the_DT most_RBS
        common_JJ cause_NN of_IN disability_NN in_IN children_NNS ,_, its_PRP$ etiology_NN is_VBZ
        unknown_JJ ._. Immune_NNP dysregulation_NN appears_VBZ to_TO play_VB a_DT key_JJ
        pathogenic_JJ role_NN ,_, as_IN circulating_VBG autoantibodies_NNS are_VBP common_JJ
        in_IN patients_NNS with_IN certain_JJ JRA_NNP clinical_JJ subtypes_NNS [_NN 1_CD 2_CD 3_CD 4_CD 5_CD
        6_CD 7_CD ]_NN ._. Two_CD recent_JJ studies_NNS have_VBP shown_VBN a_DT highly_RB significant_JJ
        association_NN between_IN early-onset_JJ pauciarticular_NN JRA_NNP and_CC
        circulating_VBG antibodies_NNS to_TO the_DT 43_CD -_: kDa_NN nuclear_JJ protein_NN DEK_NNP [_NN
        8_CD 9_CD ]_NN ._. Although_IN circulating_VBG DEK_NNP antibodies_NNS have_VBP
        subsequently_RB been_VBN found_VBN in_IN children_NNS and_CC adults_NNS with_IN other_JJ
        autoimmune_JJ diseases_NNS [_NN 10_CD 11_CD ]_NN ,_, these_DT two_CD studies_NNS did_VBD
        reveal_VB that_IN children_NNS with_IN JRA_NNP are_VBP significantly_RB more_RBR likely_JJ
        to_TO have_VB anti-_NN DEK_NNP antibodies_NNS than_IN are_VBP children_NNS without_IN
        rheumatic_JJ disease_NN ._. Children_NNS with_IN pauciarticular-onset_JJ JRA_NNP
        were_VBD also_RB significantly_RB more_RBR likely_JJ to_TO have_VB anti-_NN DEK_NNP
        antibodies_NNS than_IN were_VBD children_NNS with_IN polyarticular-onset_JJ or_CC
        systemic-onset_JJ JRA_NNP or_CC other_JJ rheumatic_JJ diseases_NNS ._. Among_IN
        children_NNS with_IN pauciarticular_NN JRA_NNP ,_, DEK_NNP autoantibodies_NNS were_VBD
        significantly_RB more_RBR common_JJ in_IN those_DT with_IN JRA-associated_NNP
        uveitis_NNS than_IN in_IN those_DT without_IN eye_NN disease_NN [_NN 8_CD 9_CD ]_NN ._. DEK_NNP
        reactivity_NN was_VBD also_RB found_VBN to_TO be_VB strongly_RB associated_VBN with_IN
        onset_NN of_IN any_DT JRA_NNP subtype_NN before_IN age_NN 6_CD years_NNS [_NN 8_CD ]_NN ._.
        DEK_NNP is_VBZ a_DT nuclear_JJ protein_NN that_WDT is_VBZ not_RB structurally_RB
        related_VBN to_TO any_DT known_VBN family_NN of_IN proteins_NNS [_NN 12_CD 13_CD ]_NN ._.
        Although_IN it_PRP may_MD also_RB participate_VB in_IN DNA_NNP replication_NN and_CC RNA_NNP
        processing_NN [_NN 14_CD 15_CD ]_NN ,_, we_PRP have_VBP identified_VBN DEK_NNP as_IN a_DT
        DNA-binding_NNP protein_NN that_WDT recognizes_VBZ the_DT TG-rich_NNP peri-_NN 
        ets_NNS (_( pets_NNS )_) regulatory_JJ element_NN in_IN the_DT
        human_JJ immunodeficiency_NN virus_NN type_NN 2_CD (_( HIV-_NNP 2_LS )_) enhancer_NN [_NN 16_CD ]_NN
        ._. The_DT pets_NNS site_NN is_VBZ important_JJ in_IN mediating_VBG HIV-_NNP 2_CD enhancer_NN
        stimulation_NN in_IN activated_VBN T_NN cells_NNS and_CC monocytes_NNS [_NN 17_CD 18_CD 19_CD ]_NN
        ,_, suggesting_VBG that_IN DEK_NNP may_MD play_VB an_DT immunomodulatory_NN role_NN as_IN
        it_PRP participates_VBZ in_IN transcriptional_NN activation_NN through_IN this_DT
        and_CC related_VBN sites_NNS ._.
        Observed_NNP sequence_NN similarity_NN between_IN the_DT DEK-binding_NNP
        site_NN in_IN HIV-_NNP 2_CD and_CC the_DT highly_RB conserved_JJ Y-_NNP box_NN regulatory_JJ
        element_NN in_IN MHC_NNP class_NN II_NNP gene_NN promoters_NNS pointed_VBD to_TO the_DT Y_NNP box_NN
        as_IN one_CD possible_RB related_VBN site_NN ._. NF-Y_NNP binding_VBG to_TO the_DT MHC_NNP class_NN
        II_NNP gene_NN Y_NNP box_NN anchors_NNS a_DT complex_JJ assembly_NN of_IN nuclear_JJ
        proteins_NNS that_WDT occupies_VBZ several_JJ regulatory_JJ elements_NNS over_IN a_DT
        great_JJ distance_NN [_NN 20_CD 21_CD 22_CD ]_NN ._. In_IN the_DT 
        DQA_NNP 1_CD promoter_NN Y_NNP box_NN ,_, a_DT reverse_NN CCAAT_NNP
        motif_NN with_IN a_DT partially_RB overlapping_VBG TG-rich_NNP sequence_NN shares_NNS
        sequence_NN identity_NN with_IN the_DT HIV-_NNP 2_CD DEK-binding_NNP site_NN at_IN 7_CD of_IN
        10_CD positions_NNS (_( Fig_NNP ._. 1_LS )_) ._. In_IN the_DT 
        DQA_NNP 1_CD *_NN 0501_CD allele_NN ,_, which_WDT is_VBZ highly_RB
        associated_VBN with_IN predisposition_NN to_TO autoimmune_JJ disease_NN [_NN 23_CD
        24_CD 25_CD 26_CD 27_CD ]_NN ,_, the_DT Y_NNP box_NN contains_VBZ a_DT single-nucleotide_JJ
        polymorphism_NN that_WDT reduces_VBZ sequence_NN identity_NN to_TO 6_CD of_IN 10_CD
        positions_NNS ._. We_PRP hypothesized_VBN that_IN DEK_NNP could_MD bind_NN in_IN a_DT
        sequence-specific_JJ manner_NN to_TO the_DT Y-_NNP box_NN motifs_NNS in_IN the_DT
        promoter_NN regions_NNS of_IN several_JJ class_NN II_NNP MHC_NNP genes_NNS ,_, and_CC that_DT
        gene-_NN and_CC allele-specific_JJ Y-_NNP box_NN polymorphisms_NNS could_MD affect_VB
        DEK_NNP binding_JJ activity_NN ._. In_IN this_DT study_NN ,_, we_PRP examine_VBP the_DT
        characteristics_NNS of_IN DEK_NNP binding_VBG to_TO the_DT Y-_NNP box_NN sequences_NNS of_IN 
        DQA_NNP 1_CD *_NN 0101_CD ,_, DQA_NNP 1_CD *_NN 0501_CD ,_, DRA_NNP ,_, DQB_NNP ,_, and_CC 
        DRB_NNP ._. We_PRP also_RB confirm_VBP participation_NN
        of_IN DEK_NNP with_IN NF-Y_NNP in_IN the_DT 
        DQA_NNP 1_CD Y-_NNP box_NN binding_JJ complex_NN and_CC
        localize_NN specific_JJ DEK_NNP binding_VBG within_IN this_DT sequence_NN ._. As_IN the_DT
        Y-_NNP box_NN promoter_NN element_NN is_VBZ crucial_JJ to_TO the_DT regulation_NN of_IN MHC_NNP
        class_NN II_NNP gene_NN expression_NN ,_, sequence-specific_JJ binding_VBG to_TO this_DT
        motif_NN indicates_VBZ a_DT potential_JJ role_NN for_IN DEK_NNP in_IN modulating_VBG
        normal_JJ and_CC abnormal_JJ immune_JJ response_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cell_NNP culture_NN and_CC preparation_NN of_IN nuclear_JJ
          extracts_NNS
          Cultured_NNP cell_NN lines_NNS were_VBD grown_VBN and_CC harvested_VBN and_CC
          nuclear_JJ extracts_NNS were_VBD prepared_VBN from_IN resting_VBG cells_NNS as_RB
          previously_RB described_VBD [_NN 28_CD 29_CD ]_NN ._.
        
        
          Preparation_NNP of_IN partially_RB purified_JJ recombinant_JJ DEK_NNP
          protein_NN
          Construction_NNP of_IN the_DT poly-histidine-tagged_JJ DEK_NNP
          bacterial_JJ expression_NN vector_NN is_VBZ described_VBN elsewhere_RB [_NN 16_CD ]_NN
          ._. Full-length_NNP DEK_NNP or_CC antisense_NN DEK_NNP was_VBD prepared_VBN from_IN
          cultures_NNS grown_VBN from_IN individual_JJ colonies_NNS to_TO log_VB phase_NN ,_,
          induced_VBN with_IN 1_CD mm_NN isopropyl_NN thiogalactose_NN ,_, and_CC harvested_VBN
          by_IN centrifugation_NN after_IN 4_CD hours_NNS ._. Recombinant_NNP protein_NN was_VBD
          purified_JJ from_IN bacterial_JJ lysates_NNS in_IN accordance_NN with_IN the_DT
          published_VBN method_NN for_IN the_DT QIA_NNP 
          express_VB system_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_,
          CA_NNP ,_, USA_NNP )_) with_IN variations_NNS in_IN Buffers_NNP B_NNP and_CC D_NNP as_IN noted_VBN in_IN
          Additional_JJ file_NN :_: 1_CD ._. Procedures_NNP were_VBD carried_VBN out_RB at_IN 4_CD °_NN C_NNP ;_:
          dialyzed_JJ recombinant_JJ DEK_NNP protein_NN (_( rDEK_NN )_) was_VBD stored_VBN at_IN
          -_: 80_CD °_NN C_NNP ._.
          Additional_JJ file_NN 1_CD
          
          Buffer_NNP B_NNP (_( 6_CD M_NNP urea_NN ,_, 0_CD ._. 1_CD M_NNP NaH_NNP 
          2_CD PO_NNP 
          4_CD ,_, 10_CD mm_NN Tris-l_NNP ,_, 0_CD ._. 1_CD M_NNP KCl_NNP )_) ,_, used_VBN for_IN
          cell_NN lysis_NNS and_CC protein_NN elution_NN ,_, was_VBD prepared_VBN with_IN the_DT
          addition_NN of_IN imidazole_NN (_( final_JJ concentration_NN 25_CD mm_NN )_) and_CC
          urea_NN (_( final_JJ concentration_NN approximately_RB 8_CD M_NNP )_) ._. Qiagen_NNP
          Ni-_NNP NTA_NNP Superflow_NNP resin_NN was_VBD equilibrated_JJ with_IN modified_VBN
          buffer_NN B_NNP before_IN being_VBG combined_VBN with_IN the_DT cell_NN lysate_NN ._. The_DT
          cell_NN lysate-resin_JJ combination_NN was_VBD incubated_JJ at_IN 4_CD °_NN C_NNP for_IN
          1_CD ._. 5_CD hours_NNS ._. Purified_NNP protein_NN was_VBD eluted_JJ from_IN the_DT column_NN
          with_IN buffer_NN B_NNP containing_VBG 100_CD -_: 250_CD mm_NN imidazole_NN ._. The_DT
          presence_NN and_CC size_NN of_IN rDEK_NN bands_NNS were_VBD verified_VBN by_IN western_JJ
          blotting_VBG ._. Protein_NNP in_IN positive_JJ elution_NN fractions_NNS was_VBD
          refolded_JJ to_TO native_JJ structure_NN by_IN serial_NN dialysis_NN against_IN
          buffer_NN D_NNP (_( 20_CD mm_NN HEPES_NNP ,_, 0_CD ._. 1_CD M_NNP KCl_NNP ,_, 0_CD ._. 2_CD mm_NN EDTA_NNP ,_, 0_CD ._. 5_CD mm_NN
          dithiothreitol_NN ,_, 0_CD ._. 5_CD mm_NN phenylmethylsulfonyl_NN fluoride_NN ,_, 20_CD %_NN
          glycerol_NN )_) containing_VBG stepwise_NN decreasing_VBG concentrations_NNS
          of_IN urea_NN (_( 6_CD M_NNP for_IN 2_CD hours_NNS ,_, 4_CD M_NNP for_IN 2_CD hours_NNS ,_, 2_CD M_NNP for_IN 2_CD
          hours_NNS ,_, no_DT urea_NN for_IN 12_CD hours_NNS )_) ._.
          Click_NNP here_RB for_IN file_NN
        
        
          Preparation_NNP of_IN FLAG-DEK_NNP
          A_DT FLAG-tagged_NNP DEK_NNP adenoviral_NN vector_NN constructed_VBN by_IN the_DT
          University_NNP of_IN Michigan_NNP Vector_NNP Core_NNP was_VBD used_VBN to_TO transduce_NN
          T_NN 98_CD G_NNP cells_NNS (_( ATCC_NNP )_) by_IN incubation_NN for_IN 48_CD hours_NNS before_IN
          harvesting_NN for_IN immunoprecipitation_NN ._. FLAG-DEK_NNP was_VBD
          immunoprecipitated_JJ using_VBG anti-_NN FLAG_NNP resin_NN (_( Sigma-_NNP Aldrich_NNP ,_,
          St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS
          instructions_NNS and_CC was_VBD eluted_JJ by_IN competition_NN with_IN peptide_NN
          containing_VBG three_CD FLAG_NNP recognition_NN epitopes_NNS ._.
        
        
          Electrophoretic_NNP mobility_NN shift_NN assays_NNS
          (_( EMSAs_NNP )_)
          EMSAs_NNP were_VBD carried_VBN out_IN as_RB previously_RB described_VBD [_NN 30_CD ]_NN
          ,_, using_VBG 0_CD ._. 1_CD -_: 0_CD ._. 25_CD ng_NN of_IN radiolabeled_JJ oligonucleotide_NN probe_NN
          (_( 2_CD ._. 5_LS ×_NN 10_CD 4_CD counts_VBZ per_IN minute_NN )_) per_IN 15_CD μl_NN binding_JJ reaction_NN
          and_CC 5_CD μg_NN of_IN nuclear_JJ extract_NN (_( except_IN as_IN noted_VBN )_) or_CC <_NN 1_CD μg_NN
          of_IN rDEK_NN ._. For_IN competition_NN EMSAs_NNP ,_, unlabeled_JJ double-stranded_JJ
          oligonucleotide_NN was_VBD added_VBN to_TO reaction_NN mixtures_NNS before_IN the_DT
          radiolabeled_JJ probe_NN ._. For_IN antibody_NN supershift_NN of_IN binding_JJ
          complexes_NNS ,_, 1_CD μl_NN anti-_NN NF-YA_NNP antibody_NN (_( gift_NN of_IN JP-Y_NNP Ting_NNP )_)
          or_CC 1_CD μl_NN high-titer_JJ anti-_NN DEK_NNP human_JJ serum_NN (_( gift_NN of_IN W_NNP Szer_NNP [_NN
          9_CD ]_NN )_) or_CC 2_CD -_: 3_CD μl_NN control_NN human_JJ serum_NN was_VBD added_VBN to_TO the_DT
          binding_JJ reaction_NN ,_, and_CC the_DT mixture_NN was_VBD incubated_JJ on_IN ice_NN
          for_IN 2_CD hours_NNS before_IN the_DT probe_NN was_VBD added_VBN ._.
        
        
          Sequence_NNP of_IN oligonucleotide_NN probes_NNS and_CC
          competitors_NNS
          See_VB Fig_NNP ._. 1_LS ._.
        
        
          Measurement_NNP of_IN apparent_JJ dissociation_NN constants_NNS
          using_VBG EMSA_NNP
          The_DT 32_CD P_NN end-labeled_JJ oligonucleide_NN probe_NN (_( 5_CD nM_NN )_) was_VBD
          incubated_JJ with_IN immunoprecipitation-purified_JJ FLAG-rDEK_NNP in_IN
          a_DT range_NN of_IN concentrations_NNS from_IN one_CD tenth_NN to_TO 10_CD times_NNS the_DT
          estimated_VBN K_NNP 
          d_SYM [_NN app_NN ]_NN (_( apparent_JJ dissociation_NN
          constant_JJ )_) as_IN described_VBN elsewhere_RB [_NN 31_CD ]_NN ._. Protein-bound_NNP
          DNA_NNP was_VBD separated_JJ from_IN free_JJ probe_NN as_IN for_IN EMSA_NNP in_IN 1_CD ×_NN TBE_NNP
          (_( Tris-borate-_NNP EDTA_NNP buffer_NN :_: Tris_NNP 89_CD mM_NN ,_, borate_NN 89_CD mM_NN ,_, EDTA_NNP
          2_CD mM_NN )_) ._. The_DT dried_VBN gel_NN was_VBD exposed_VBN to_TO a_DT phosphor_NN screen_NN
          overnight_JJ ,_, and_CC the_DT bands_NNS were_VBD quantified_VBN using_VBG a_DT
          Molecular_NNP Dynamics_NNP Storm_NN 840_CD Phosphorimager_NNP with_IN
          Image-_NNP Quant_NN Software_NNP ._. The_DT data_NNS were_VBD fit_VBN via_IN nonlinear_NN
          least-squares_JJ regression_NN to_TO the_DT single-site_JJ binding_JJ
          isotherm_NN :_:
          %_NN free_JJ DNA_NNP =_SYM K_NNP 
          d_SYM [_NN app_NN ]_NN /_NN (_( K_NNP 
          d_SYM [_NN app_NN ]_NN +_NN [_NN protein_NN ]_NN )_) ._.
          From_IN this_DT equation_NN ,_, the_DT apparent_JJ K_NNP 
          d_SYM corresponds_NNS to_TO the_DT protein_NN
          concentration_NN at_IN which_WDT half_NN of_IN the_DT DNA_NNP is_VBZ bound_VBN [_NN 31_CD ]_NN
          ._.
        
        
          DNAse_NNP I_PRP protection_NN assay_NN
          The_DT 148_CD -_: bp_NN probe_NN included_VBD 
          DQA_NNP 1_CD *_NN 0101_CD promoter_NN sequence_NN from_IN
          -_: 53_CD to_TO -_: 200_CD ._. PCR_NNP primer_NN (_( 200_CD ng_NN )_) for_IN probe_NN sequence_NN was_VBD
          end-labeled_JJ with_IN 32_CD Pγ-_NNP ATP_NNP and_CC T_NN 4_CD polynucleotide_NN kinase_NN
          (_( New_NNP England_NNP Biolabs_NNP ,_, Beverly_NNP ,_, MA_NNP ,_, USA_NNP )_) ,_, and_CC was_VBD column_NN
          purified_JJ ._. Labeled_NNP antisense_NN primer_NN (_( 200_CD ng_NN )_) and_CC 200_CD ng_NN
          unlabeled_JJ sense_NN strand_NN primer_NN (_( or_CC vice_NN versa_RB )_) were_VBD used_VBN
          in_IN each_DT 50_CD ._. 5_LS -_: μl_NN PCR_NNP reaction_NN ,_, with_IN 0_CD ._. 2_CD mM_NN dNTP_NN ,_, 1_CD ._. 5_CD mM_NN
          MgCl_NNP 
          2_CD ,_, 5_CD μl_NN 10_CD X_NNP PCR_NNP Buffer_NNP (_( Invitrogen_NNP ,_,
          Carlsbad_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, and_CC 1_CD μg_NN Namalwa_NNP genomic_JJ DNA_NNP ._. 
          Taq_NNP polymerase_NN (_( Invitrogen_NNP )_) was_VBD
          added_VBN at_IN 80_CD °_NN C_NNP after_IN a_DT 94_CD °_NN C_NNP '_POS hot_JJ start_NN ,_, '_'' initiating_VBG 35_CD
          cycles_NNS of_IN PCR_NNP :_: 94_CD °_NN C_NNP for_IN 45_CD s_VBZ ,_, 55_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, and_CC 72_CD °_NN C_NNP for_IN
          90_CD s_VBZ ,_, with_IN final_JJ extension_NN at_IN 72_CD °_NN C_NNP for_IN 10_CD min_NN ._. PCR_NNP
          products_NNS were_VBD purified_JJ with_IN a_DT High_NNP Pure_NNP PCR_NNP Product_NNP
          Purification_NNP Kit_NNP (_( Roche_NNP Applied_NNP Science_NNP ,_, Indianapolis_NNP ,_,
          IN_IN ,_, USA_NNP )_) and_CC then_RB used_VBN at_IN 2_CD ._. 5_CD ×_NN 10_CD 4_CD CPM_NNP /_NN 2_CD μl_NN ._. DNase_NNP I_PRP
          digestion_NN reaction_NN and_CC footprinting_VBG gel_NN followed_VBN
          published_VBN techniques_NNS [_NN 16_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Y-_NNP box_NN binding_JJ activity_NN in_IN nuclear_JJ extracts_NNS is_VBZ gene-_NN
          and_CC allele-specific_JJ
          The_DT similarity_NN of_IN the_DT 
          DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN sequence_NN to_TO the_DT
          HIV-_NNP 2_CD DEK-binding_NNP site_NN (_( see_VB Fig_NNP ._. 1_LS )_) first_RB led_VBN us_PRP to_TO
          investigate_VB whether_IN DEK_NNP in_IN nuclear_JJ extracts_NNS binds_NNS to_TO MHC_NNP
          class_NN II_NNP Y-_NNP box_NN regulatory_JJ elements_NNS 
          in_IN vitro_NN ._. With_IN a_DT double-stranded_JJ
          oligonucleotide_NN probe_NN containing_VBG the_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN sequence_NN ,_, EMSAs_NNP
          revealed_VBD similar_JJ binding_JJ activity_NN in_IN nuclear_JJ extracts_NNS
          from_IN B_NNP lymphoid_NN (_( Namalwa_NNP )_) ,_, T_NN lymphoid_NN (_( Jurkat_NNP ,_, CEM_NNP )_) ,_,
          monocytoid_NN (_( U_NNP 937_CD )_) ,_, and_CC HeLa_NNP cell_NN lines_NNS (_( Fig_NNP ._. 2_LS )_) ,_, and_CC in_IN
          nuclear_JJ extracts_NNS from_IN SKW_NNP 6_CD ._. 4_CD (_( B_NNP lymphoid_NN )_) ,_, KG-_NNP 1_CD (_( T_NN
          lymphoid_NN )_) ,_, and_CC HL-_NNP 60_CD (_( monocytoid_NN )_) cell_NN lines_NNS (_( not_RB shown_VBN )_) ._.
          Electrophoretic_NNP patterns_NNS with_IN a_DT probe_NN corresponding_JJ to_TO
          the_DT 
          DQA_NNP 1_CD *_NN 0501_CD Y-_NNP box_NN sequence_NN ,_, which_WDT
          diverges_NNS from_IN the_DT 
          DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN sequence_NN by_IN a_DT
          single_JJ base_NN pair_NN within_IN the_DT highly_RB conserved_JJ reverse_NN
          CCAAT_NNP sequence_NN ,_, appear_VB to_TO vary_VB with_IN the_DT cell_NN type_NN ,_, and_CC
          binding_JJ appears_VBZ weaker_JJR than_IN with_IN the_DT 
          DQA_NNP 1_CD *_NN 0101_CD probe_NN (_( see_VB Fig_NNP ._. 2_LS )_) ._.
          Competition_NNP EMSAs_NNP demonstrated_VBD sequence-specificity_JJ of_IN
          the_DT 
          DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN binding_JJ activity_NN
          (_( Fig_NNP ._. 3_LS a_DT )_) ._. Unlabeled_NNP 
          DQA_NNP 1_CD *_NN 0101_CD oligonucleotides_NNS
          successfully_RB competed_VBN for_IN strong_JJ binding_JJ activity_NN seen_VBN in_IN
          nuclear_JJ extracts_NNS from_IN the_DT Namalwa_NNP B_NNP cell_NN line_NN (_( Fig_NNP ._. 3_LS a_DT ,_,
          lanes_NNS 3_CD and_CC 4_LS )_) ,_, whereas_IN unlabeled_JJ 
          DQA_NNP 1_CD *_NN 0501_CD Y-_NNP box_NN sequence_NN competed_VBN
          less_RBR well_RB (_( Fig_NNP ._. 3_LS a_DT ,_, lanes_NNS 5_CD and_CC 6_CD )_) ._. There_EX was_VBD no_DT
          competition_NN when_WRB the_DT Y-_NNP box_NN reverse_NN CCAAT_NNP motif_NN was_VBD
          mutated_VBN at_IN all_DT five_CD positions_NNS (_( Fig_NNP ._. 3_LS a_DT ,_, lanes_NNS 7_CD and_CC 8_CD )_) ,_,
          nor_CC with_IN the_DT unrelated_JJ HIV-_NNP 1_CD κB_NN sequence_NN (_( lane_NN 10_CD )_) ._. DEK_NNP
          has_VBZ been_VBN shown_VBN to_TO bind_NN to_TO the_DT HIV-_NNP 2_CD pets_NNS site_NN [_NN 16_CD ]_NN ,_,
          but_CC oligonucleotides_NNS containing_VBG this_DT sequence_NN also_RB failed_VBD
          to_TO compete_VB significantly_RB (_( lane_NN 9_CD )_) ,_, suggesting_VBG that_WDT
          factors_NNS other_JJ than_IN DEK_NNP play_VB a_DT role_NN in_IN determining_VBG the_DT
          specificity_NN of_IN this_DT complex_NN ._. In_IN particular_JJ ,_, NF-Y_NNP is_VBZ the_DT
          predominant_NN nuclear_JJ factor_NN binding_VBG to_TO the_DT Y_NNP box_NN [_NN 21_CD ]_NN ,_,
          and_CC the_DT HIV-_NNP 2_CD pets_NNS site_NN does_VBZ not_RB contain_VB the_DT reverse_NN
          CCAAT_NNP sequence_NN required_VBN for_IN NF-Y_NNP binding_JJ ._.
          The_DT consensus_NN (_( 
          HLA-DRA_NNP )_) Y-_NNP box_NN sequence_NN differs_VBZ
          from_IN the_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD Y_NNP box_NN by_IN a_DT single_JJ
          nucleotide_NN immediately_RB 5_CD '_POS of_IN the_DT reverse_NN CCAAT_NNP pentamer_NN ;_:
          this_DT single-nucleotide_JJ polymorphism_NN significantly_RB changes_VBZ
          the_DT electrophoretic_JJ pattern_NN (_( Fig_NNP ._. 3_LS b_SYM )_) in_IN comparison_NN with_IN
          that_DT seen_VBN with_IN the_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD probe_NN ._. 
          HLA-DQA_NNP 1_CD *_NN 0101_CD oligonucleotide_NN also_RB
          competes_VBZ poorly_RB with_IN the_DT consensus_NN Y-_NNP box_NN probe_NN for_IN
          binding_JJ (_( Fig_NNP ._. 3_LS b_SYM ,_, lanes_NNS 5_CD -_: 6_CD )_) ._. Divergence_NNP of_IN the_DT 
          HLA-DQA_NNP 1_CD *_NN 0501_CD Y-_NNP box_NN sequence_NN at_IN one_CD
          position_NN within_IN the_DT required_JJ NF-Y_NNP binding_JJ site_NN reduces_VBZ
          its_PRP$ ability_NN to_TO compete_VB with_IN the_DT 
          DRA_NNP Y-_NNP box_NN probe_NN (_( Fig_NNP ._. 3_LS b_SYM ,_, lanes_NNS
          7_CD -_: 8_CD )_) as_RB much_JJ as_IN does_VBZ mutation_NN of_IN all_DT five_CD nucleotides_NNS
          within_IN the_DT CCAAT_NNP sequence_NN (_( Fig_NNP ._. 3_LS b_SYM ,_, lanes_NNS 9_CD -_: 10_CD )_) ._.
        
        
          Both_DT DEK_NNP and_CC NF-Y_NNP participate_VBP in_IN the_DT HLA-DQA_NNP 1_CD Y-_NNP box_NN
          binding_JJ complex_JJ
          Participation_NNP of_IN both_DT DEK_NNP and_CC NF-Y_NNP in_IN the_DT 
          DQA_NNP 1_CD Y-_NNP box_NN binding_JJ complex_NN was_VBD
          confirmed_VBN by_IN using_VBG high-titer_JJ anti-_NN DEK_NNP antiserum_NN (_( gift_NN of_IN
          W_NNP Szer_NNP [_NN 9_CD ]_NN )_) and_CC monoclonal_NN antibody_NN to_TO the_DT NF-YA_NNP
          subunit_NN of_IN the_DT Y-_NNP box_NN binding_JJ factor_NN (_( gift_NN of_IN JP-Y_NNP Ting_NNP )_)
          to_TO further_VB retard_VB the_DT mobility_NN of_IN the_DT 
          DQA_NNP 1_CD Y-_NNP box_NN binding_JJ complex_JJ
          (_( '_POS supershifting_VBG '_POS )_) (_( Fig_NNP ._. 4_LS ,_, lanes_NNS 3_CD -_: 4_LS )_) ._. Preincubation_NNP of_IN
          Namalwa_NNP cell_NN nuclear_JJ extracts_NNS with_IN antibodies_NNS to_TO NF-YA_NNP
          also_RB retards_NNS the_DT binding_JJ complex_JJ (_( Fig_NNP ._. 4_LS ,_, lane_NN 5_LS )_) ,_,
          leaving_VBG a_DT residual_JJ band_NN (_( arrow_NN )_) which_WDT can_MD be_VB attributed_VBN
          to_TO distinct_JJ DEK_NNP binding_JJ activity_NN ._. Preincubation_NNP with_IN both_DT
          antibodies_NNS results_NNS in_IN further_JJ retardation_NN of_IN the_DT binding_JJ
          complex_NN to_TO form_VB a_DT doublet_NN (_( Fig_NNP ._. 4_LS ,_, lane_NN 6_CD )_) ._. The_DT same_JJ
          electrophoretic_JJ patterns_NNS were_VBD seen_VBN after_IN preincubation_NN of_IN
          nuclear_JJ extracts_NNS from_IN the_DT CEM_NNP T_NN lymphocytoid_NN cell_NN line_NN
          with_IN anti-_NN DEK_NNP and_CC anti-_NN NF-YA_NNP antibodies_NNS (_( data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Recombinant_NNP DEK_NNP protein_NN binds_NNS in_IN a_DT
          sequence-specific_JJ manner_NN to_TO the_DT DQA_NNP 1_CD Y_NNP box_NN but_CC not_RB to_TO the_DT
          DRA_NNP (_( consensus_NN )_) Y_NNP box_NN
          Having_VBG established_VBN that_IN DEK_NNP and_CC NF-Y_NNP in_IN nuclear_JJ
          extracts_NNS participate_VBP in_IN the_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD binding_JJ complex_NN ,_, we_PRP
          used_VBD recombinant_JJ full-length_JJ DEK_NNP (_( rDEK_NN )_) to_TO determine_VB
          whether_IN it_PRP alone_RB can_MD bind_NN to_TO Y-_NNP box_NN motifs_NNS and_CC to_TO examine_VB
          how_WRB gene-_NN and_CC allele-specific_JJ sequence_NN polymorphisms_NNS
          alter_VBP its_PRP$ binding_JJ ._. The_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN sequence_NN does_VBZ
          bind_NN rDEK_NN specifically_RB ,_, with_IN unlabeled_JJ probe_NN sequence_NN
          competing_VBG successfully_RB for_IN binding_JJ (_( Fig_NNP ._. 5_LS a_DT ,_, lanes_NNS 4_CD -_: 6_CD )_) ._.
          In_IN contrast_NN ,_, despite_IN its_PRP$ identity_NN at_IN 9_CD of_IN 10_CD positions_NNS ,_,
          unlabeled_JJ consensus_NN (_( 
          DRA_NNP )_) Y-_NNP box_NN sequence_NN (_( Fig_NNP ._. 5_LS a_DT ,_,
          lanes_NNS 7_CD -_: 8_CD )_) competes_VBZ very_RB poorly_RB against_IN the_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN probe_NN ._. 
          DQA_NNP 1_CD *_NN 0501_CD Y-_NNP box_NN sequence_NN (_( Fig_NNP ._. 5_LS a_DT ,_,
          lanes_NNS 9_CD -_: 10_CD )_) competes_VBZ only_RB slightly_RB less_RBR well_RB than_IN does_VBZ 
          DQA_NNP 1_CD *_NN 0101_CD ,_, indicating_VBG that_IN a_DT
          change_NN in_IN the_DT residue_NN at_IN position_NN 7_CD does_VBZ not_RB prevent_VB rDEK_NN
          binding_JJ ._. Mutation_NNP of_IN the_DT reverse_NN CCAAT_NNP sequence_NN ,_, however_RB ,_,
          eliminates_VBZ effective_JJ competition_NN for_IN binding_VBG to_TO the_DT 
          DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN sequence_NN (_( Fig_NNP ._. 5_LS a_DT ,_,
          lanes_NNS 11_CD -_: 12_CD )_) ._. Taken_VBN together_RB ,_, these_DT results_NNS indicate_VBP that_DT
          substitution_NN of_IN adenine_NN at_IN position_NN 3_CD in_IN the_DT 
          DQA_NNP 1_CD Y_NNP box_NN for_IN guanine_NN in_IN the_DT
          consensus_NN Y-_NNP box_NN sequence_NN significantly_RB strengthens_VBZ DEK_NNP
          binding_JJ ,_, as_IN do_VBP bases_NNS at_IN positions_NNS 5_CD and_CC 6_CD in_IN the_DT reverse_NN
          CCAAT_NNP sequence_NN ._.
          Further_RB characterization_NN of_IN rDEK_NN binding_VBG to_TO the_DT
          polymorphic_JJ 
          DQA_NNP 1_CD *_NN 0501_CD Y-_NNP box_NN sequence_NN and_CC to_TO the_DT
          consensus_NN (_( 
          HLA-DRA_NNP )_) Y-_NNP box_NN sequence_NN
          establishes_VBZ a_DT relative_JJ hierarchy_NN of_IN DEK_NNP binding_JJ activity_NN
          (_( Fig_NNP ._. 5_LS b_SYM )_) ._. With_IN the_DT 
          DQA_NNP 1_CD *_NN 0501_CD probe_NN ,_, unlabelled_JJ 
          DQA_NNP 1_CD *_NN 0101_CD sequence_NN (_( Fig_NNP ._. 5_LS b_SYM ,_, lane_NN
          3_LS )_) competed_VBN less_RBR well_RB than_IN did_VBD unlabelled_JJ probe_NN ._. DRA_NNP Y_NNP
          box_NN sequence_NN (_( Fig_NNP ._. 5_LS b_SYM ,_, lane_NN 4_LS )_) and_CC CCAAT_NNP mutant_JJ sequence_NN
          (_( not_RB shown_VBN )_) did_VBD not_RB compete_VB for_IN binding_JJ ._. Inability_NNP of_IN the_DT
          
          HLA-DRA_NNP Y-_NNP box_NN sequence_NN to_TO compete_VB
          with_IN the_DT 
          DQA_NNP 1_CD *_NN 0501_CD probe_NN again_RB indicates_VBZ the_DT
          relative_JJ importance_NN of_IN the_DT adenine_NN residue_NN immediately_RB 5_CD '_POS
          to_TO the_DT reverse_NN CCAAT_NNP for_IN DEK_NNP binding_JJ ._. With_IN the_DT 
          DRA_NNP Y-_NNP box_NN sequence_NN as_IN probe_NN (_( Fig_NNP ._.
          5_LS b_SYM ,_, lanes_NNS 6_CD -_: 10_CD )_) ,_, the_DT unlabelled_JJ probe_NN sequence_NN competes_VBZ
          less_RBR well_RB than_IN do_VBP any_DT of_IN the_DT other_JJ Y-_NNP box_NN sequences_NNS ,_,
          suggesting_VBG that_DT rDEK_NN alone_RB binds_NNS to_TO this_DT sequence_NN
          nonspecifically_RB and_CC with_IN low_JJ affinity_NN ._.
        
        
          Quantitative_NNP assessment_NN of_IN rDEK_NN binding_JJ to_TO related_VBN
          DQ-and_NNP DR-_NNP Y-_NNP box_NN sequences_NNS
          Quantification_NNP of_IN the_DT apparent_JJ dissociation_NN constant_JJ
          (_( K_NNP 
          d_SYM [_NN app_NN ]_NN )_) for_IN rDEK_NN binding_JJ to_TO related_VBN
          class_NN II_NNP MHC_NNP Y-_NNP box_NN motifs_NNS validates_NNS the_DT relative_JJ
          hierarchy_NN of_IN DEK_NNP binding_JJ activity_NN described_VBD above_IN ,_, and_CC
          further_JJ emphasizes_VBZ the_DT contribution_NN of_IN gene-specific_JJ
          Y-_NNP box_NN polymorphisms_NNS to_TO DEK_NNP binding_JJ activity_NN ._. As_IN shown_VBN in_IN
          Table_NNP 1_CD ,_, DEK_NNP binds_NNS more_RBR strongly_RB to_TO Y-_NNP box_NN sequences_NNS in_IN
          either_DT 
          DQA_NNP 1_CD allele_NN than_IN it_PRP does_VBZ to_TO any_DT of_IN
          the_DT other_JJ 
          DR_NNP -_: or_CC 
          DQ_NNP -_: related_VBN Y-_NNP box_NN sequences_NNS ._. It_PRP
          binds_NNS least_JJS well_RB to_TO the_DT 
          DRA_NNP (_( consensus_NN )_) Y-_NNP box_NN motif_NN ,_, with_IN a_DT
          K_NNP 
          d_SYM [_NN app_NN ]_NN that_WDT is_VBZ approximately_RB five_CD
          times_NNS that_IN for_IN the_DT 
          DQA_NNP 1_CD sequences_NNS ._. The_DT K_NNP 
          d_SYM [_NN app_NN ]_NN for_IN DEK_NNP binding_JJ to_TO 
          DQB_NNP is_VBZ approximately_RB four_CD times_NNS
          that_IN for_IN the_DT 
          DQA_NNP 1_CD sequences_NNS ,_, whereas_IN the_DT K_NNP 
          d_SYM [_NN app_NN ]_NN for_IN DEK_NNP binding_VBG to_TO the_DT 
          DRB_NNP Y-_NNP box_NN sequences_NNS ,_, especially_RB the_DT
          
          DRB_NNP alleles_NNS associated_VBN with_IN the_DT DR_NNP 4_CD
          haplotype_NN ,_, are_VBP intermediate_JJ between_IN the_DT two_CD extremes_NNS ._.
          Once_RB again_RB ,_, the_DT A-_NNP to-_NN G_NNP substitution_NN at_IN position_NN 3_CD in_IN the_DT
          Y_NNP box_NN appears_VBZ to_TO strengthen_VB DEK_NNP binding_VBG to_TO the_DT 
          DQA_NNP 1_CD Y_NNP box_NN in_IN comparison_NN with_IN the_DT 
          DRA_NNP Y_NNP box_NN ;_: allelic_JJ variation_NN in_IN the_DT
          nucleotide_NN at_IN position_NN 7_CD in_IN the_DT Y-_NNP box_NN sequence_NN (_( as_IN in_IN 
          DQA_NNP 1_CD *_NN 0501_CD and_CC in_IN the_DT DR_NNP 4_CD -_: associated_VBN
          
          DRB_NNP Y-_NNP box_NN sequence_NN )_) may_MD also_RB
          mediate_VB subtle_JJ differences_NNS in_IN DEK_NNP binding_JJ to_TO otherwise_RB
          identical_JJ sites_NNS ._. Gene-specific_NNP sequence_NN polymorphisms_NNS
          outside_IN the_DT Y_NNP box_NN per_IN se_FW could_MD also_RB explain_VB why_WRB
          dissociation_NN constants_NNS differ_VBP where_WRB Y-_NNP box_NN sequences_NNS are_VBP
          identical_JJ ,_, as_IN in_IN the_DT 
          DQB_NNP and_CC 
          DRB_NNP consensus_NN motifs_NNS ._.
        
        
          Localization_NNP of_IN DEK_NNP binding_VBG within_IN the_DT Y_NNP box_NN
          DNase_NNP I_PRP footprinting_VBG with_IN recombinant_JJ protein_NN further_RBR
          defined_VBD the_DT physical_JJ interaction_NN between_IN DEK_NNP and_CC the_DT 
          HLA-DQA_NNP 1_CD *_NN 0101_CD Y-_NNP box_NN element_NN (_( Fig_NNP ._.
          6_CD )_) ._. Using_VBG the_DT noncoding_VBG strand_NN as_IN probe_NN ,_, consistent_JJ
          protection_NN is_VBZ seen_VBN over_IN the_DT G_NNP at_IN position_NN 7_CD ,_, which_WDT is_VBZ
          polymorphic_JJ in_IN the_DT 
          DQA_NNP 1_CD *_NN 0501_CD allele_NN (_( A-_NNP for-_NN G_NNP
          substitution_NN )_) and_CC in_IN the_DT DRB_NNP alleles_NNS associated_VBN with_IN the_DT
          DR_NNP 4_CD haplotype_NN (_( C-_NNP for-_NN G_NNP substitution_NN )_) ._. Consistent_NNP
          protection_NN is_VBZ also_RB seen_VBN at_IN position_NN 2_CD ,_, adjacent_JJ to_TO the_DT
          A-_NNP for-_NN G_NNP substitution_NN that_IN diverges_NNS from_IN the_DT Y-_NNP box_NN
          consensus_NN sequence_NN ,_, although_IN there_EX is_VBZ no_DT protection_NN of_IN
          the_DT divergent_JJ base_NN itself_PRP at_IN position_NN 3_CD ._. DNase_NNP I_PRP
          protection_NN by_IN recombinant_JJ DEK_NNP extends_VBZ over_IN the_DT length_NN of_IN
          the_DT Y-_NNP box_NN sequence_NN ,_, including_VBG bases_NNS within_IN the_DT NF-Y_NNP
          binding_JJ site_NN (_( reverse_VB CCAAT_NNP sequence_NN )_) ,_, again_RB suggesting_VBG
          that_IN the_DT two_CD proteins_NNS may_MD interact_NN ._.
        
      
      
        Discussion_NNP
        All_DT antigen-presenting_JJ cells_NNS upregulate_NN MHC_NNP class_NN II_NNP
        transcription_NN in_IN response_NN to_TO immune_JJ stimulation_NN ._. We_PRP have_VBP
        previously_RB shown_VBN that_DT activation_NN of_IN promyeloid_NN cells_NNS causes_NNS
        dephosphorylation_NN of_IN DEK_NNP and_CC diminished_VBN DEK_NNP binding_VBG to_TO the_DT
        HIV-_NNP 2_CD long_JJ terminal_NN repeat_NN [_NN 16_CD 17_CD 32_CD ]_NN ._. In_IN this_DT study_NN ,_, we_PRP
        show_VBP that_DT rDEK_NN can_MD bind_NN to_TO the_DT 
        DQA_NNP 1_CD Y_NNP box_NN ,_, and_CC that_IN DEK_NNP in_IN nuclear_JJ
        extracts_NNS participates_VBZ in_IN the_DT 
        DQA_NNP 1_CD Y-_NNP box_NN binding_JJ complex_NN 
        in_IN vitro_NN ._. Thus_RB ,_, we_PRP propose_VBP a_DT model_NN
        in_IN which_WDT intracellular_NN signaling_VBG modulates_NNS the_DT ability_NN of_IN
        DEK_NNP to_TO bind_NN DNA_NNP ,_, causing_VBG alteration_NN of_IN MHC_NNP class_NN II_NNP
        transcription_NN ._. Transient_NNP transfection_NN experiments_NNS in_IN
        cultured_JJ cell_NN lines_NNS have_VBP not_RB proved_VBN useful_JJ in_IN examining_VBG
        this_DT model_NN ,_, for_IN DEK_NNP is_VBZ highly_RB expressed_VBN in_IN most_JJS cells_NNS of_IN
        hematopoietic_JJ lineage_NN ,_, and_CC further_JJ overexpression_NN has_VBZ
        resulted_VBN in_IN apparently_RB nonspecific_JJ downregulation_NN of_IN
        transcriptional_NN activity_NN (_( as_IN might_MD be_VB predicted_VBN from_IN [_NN 14_CD ]_NN
        )_) ._. For_IN this_DT reason_NN ,_, we_PRP are_VBP currently_RB pursuing_VBG other_JJ
        experimental_JJ approaches_NNS ._.
        The_DT 
        DQA_NNP 1_CD *_NN 0501_CD promoter_NN region_NN (_( QAP_NNP 4_CD ._. 1_LS )_) ,_,
        in_IN which_WDT a_DT single-base-pair_JJ polymorphism_NN in_IN the_DT Y_NNP box_NN
        significantly_RB diminishes_VBZ transcriptional_NN activity_NN [_NN 33_CD ]_NN ,_,
        is_VBZ a_DT component_NN of_IN the_DT so-called_JJ susceptibility_NN haplotype_NN
        for_IN autoimmune_JJ disease_NN ._. The_DT 
        DQA_NNP 1_CD *_NN 0501_CD allele_NN is_VBZ strongly_RB
        associated_VBN with_IN early-onset_JJ pauciarticular_NN JRA_NNP in_IN Northern_JJ
        European_JJ populations_NNS [_NN 23_CD 24_CD ]_NN and_CC with_IN increased_VBN risk_NN for_IN
        juvenile_JJ dermatomyositis_NNS [_NN 25_CD ]_NN and_CC Sjögren_NNP 's_POS syndrome_NN with_IN
        high_JJ autoantibody_NN production_NN [_NN 26_CD 27_CD ]_NN ._. In_IN our_PRP$ proposed_VBN
        model_NN ,_, aberrant_NN class_NN II_NNP MHC_NNP regulation_NN could_MD result_VB from_IN
        altered_VBN DEK_NNP binding_JJ and_CC /_NN or_CC interaction_NN with_IN NF-Y_NNP ,_, and_CC
        aberrant_NN class_NN II_NNP expression_NN may_MD alter_VB or_CC enhance_VB
        reactivity_NN against_IN DEK-derived_NNP or_CC other_JJ self_NN peptides_NNS ._. The_DT
        C-_NNP terminal_NN region_NN of_IN DEK_NNP ,_, which_WDT contains_VBZ the_DT putative_JJ
        DNA-binding_NNP domain_NN ,_, appears_VBZ to_TO be_VB most_RBS antigenic_JJ [_NN 34_CD ]_NN
        (_( and_CC K_NNP Sitwala_NNP and_CC DM_NNP Markovitz_NNP ,_, unpublished_JJ observations_NNS )_) ,_,
        raising_VBG the_DT possibility_NN that_WDT altered_VBD DNA_NNP binding_JJ may_MD expose_VB
        other_JJ masked_VBN epitopes_NNS ._. Development_NNP of_IN antibodies_NNS to_TO DEK_NNP
        could_MD even_RB be_VB a_DT primary_JJ event_NN in_IN the_DT pathogenesis_NNS of_IN JRA_NNP ,_,
        with_IN disruption_NN of_IN nuclear_JJ events_NNS due_JJ to_TO penetration_NN of_IN
        anti-_NN DEK_NNP antibodies_NNS into_IN living_VBG cells_NNS [_NN 35_CD ]_NN ._. It_PRP remains_VBZ
        to_TO be_VB determined_VBN whether_IN anti-_NN DEK_NNP antibodies_NNS are_VBP directly_RB
        involved_VBN in_IN the_DT pathogenesis_NNS of_IN autoimmune_JJ disease_NN ,_, or_CC if_IN
        they_PRP result_VBP from_IN generally_RB enhanced_JJ immunoreactivity_NN ._.
      
      
        Conclusion_NNP
        Three_CD specific_JJ findings_NNS in_IN this_DT report_NN support_NN a_DT
        potential_JJ role_NN for_IN DEK_NNP as_IN a_DT transcriptional_NN modulator_NN of_IN
        MHC_NNP class_NN II_NNP expression_NN ._. One_CD is_VBZ that_IN DEK_NNP binds_NNS to_TO the_DT 
        HLA-DQA_NNP 1_CD Y_NNP box_NN in_IN a_DT sequence-specific_JJ
        manner_NN ._. Another_DT is_VBZ that_IN NF-Y_NNP and_CC DEK_NNP both_DT participate_VB in_IN
        the_DT HLA-DQA_NNP *_NN 0101_CD Y-_NNP box_NN binding_JJ complex_NN ,_, which_WDT coordinates_VBZ
        DQ_NNP protein_NN expression_NN ._. Finally_RB ,_, DEK_NNP binds_NNS differentially_RB to_TO
        specific_JJ Y-_NNP box_NN sequences_NNS found_VBD in_IN 
        HLA-DQA_NNP 1_CD (_( *_NN 0101_CD and_CC 
        *_NN 0501_CD alleles_NNS )_) and_CC 
        HLA-DRA_NNP ,_, consistent_JJ with_IN
        observations_NNS of_IN 
        DQA_NNP 1_CD gene-specific_JJ cell-surface_JJ
        expression_NN [_NN 36_CD ]_NN and_CC allele-specific_JJ promoter_NN activity_NN [_NN
        33_CD ]_NN ._. The_DT specificity_NN of_IN rDEK_NN binding_VBG to_TO these_DT and_CC other_JJ ,_,
        related_VBD Y-_NNP box_NN sequences_NNS (_( including_VBG 
        HLA-DQB_NNP and_CC 
        HLA-DRB_NNP alleles_NNS associated_VBN with_IN the_DT
        DR_NNP 4_CD haplotype_NN )_) may_MD correlate_VBP with_IN a_DT predisposition_NN to_TO
        autoim-mune_JJ disease_NN seen_VBN with_IN certain_JJ HLA_NNP haplotypes_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        bp_NN =_SYM base_NN pair_NN (_( s_VBZ )_) ;_: EMSA_NNP =_SYM electrophoretic_JJ mobility_NN shift_NN
        assay_NN ;_: FLAG_NNP =_SYM Five_CD NH_NNP 
        2_CD -_: terminally_RB deleted_VBN epilope_NN ;_: MHC_NNP =_SYM
        Major_NNP histocompatibility_NN complex_JJ ;_: HIV_NNP =_SYM human_JJ
        immunodeficiency_NN virus_NN ;_: JRA_NNP =_SYM juvenile_JJ rheumatoid_NN
        arthritis_NN ;_: K_NNP 
        d_SYM [_NN app_NN ]_NN =_SYM apparent_JJ dissociation_NN constant_JJ ;_:
        PCR_NNP =_SYM polymerase_NN chain_NN reaction_NN ;_: pets_NNS =_SYM peri-_NN 
        ets_NNS ;_: rDEK_NN =_SYM recombinant_JJ DEK_NNP
        protein_NN ._.
      
    
  
